Previous 10 | Next 10 |
2023-05-16 14:56:55 ET Summary Blarcamesine, Aricept, and most probably simufilam are sigma-1 receptor agonists. Sigma-1 receptor agonists often produce temporary improvements in cognition for those with mild cognitive impairment and can initially stabilize the disease in mild Alz...
2023-05-14 12:00:49 ET Leqembi, the new Alzheimer's therapy developed by Biogen ( NASDAQ: BIIB ) and Eisai ( OTCPK:ESALF ) ( OTCPK:ESAIY ), could add $2B - $5B costs to Medicare annually, in the event of broader coverage, according to a recently published study. Early th...
2023-05-12 16:39:19 ET Shares of Cassava Sciences (NASDAQ: SAVA) were up 18.7% for the week, according to data provided by S&P Global Market Intelligence . The clinical-stage biotech stock closed at $22.32 last week, then rose to as high as $28.65 on Thursday, the day th...
The Cognition Maintenance Study (CMS) is a 6-month, Randomized Controlled Trial of Simufilam in Over 125 Patients with Alzheimer’s Disease. Primary Outcome Measures Are Safety and Change in Cognition Scores. Top-line Clinical Results of the CMS Are Expected in Q3 20...
2023-05-10 12:04:07 ET Summary Shorts have targeted the small biotech as a one-trick pony. Evidential data for simufilam’s biological activity outside the field of neurodegeneration promised by mid-year arrived early. Milan researchers found that simufilam increases the...
New in vitro data from Europe show that simufilam can reverse altered filamin A protein (FLNA) in pituitary tumor cells, leading to improved cell signaling. Data suggest FLNA is a central factor influencing pituitary tumor cell behavior. Data to be presented at the Europea...
2023-05-01 18:06:45 ET Cassava Sciences ( NASDAQ: SAVA ) has filed for a mixed securities shelf offering. The amount has not been determined. The filing does not necessarily indicate that a sale has begun or will occur in the future. The company indicated it plans to use t...
2023-05-01 10:41:18 ET Cassava Sciences press release ( NASDAQ: SAVA ): Q1 GAAP EPS of -$0.58. At March 31, 2023, cash and cash equivalents were $187.5 million, with no debt. For further details see: Cassava Sciences GAAP EPS of -$0.58
O ver 1,244 Alzheimer’s patients now enrolled in Phase 3 studies of simufilam. Completion of patient enrollment for Phase 3 program still expected Q4 2023. $187.5 Million Cash and Cash Equivalents at March 31, 2023. AUSTIN, Texas, May 01, 2023 (GLOBE NEWSWIRE)...
2023-04-28 23:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.6% to $117.99 on volume of 383,510,118 shares Aptevo Therapeutics Inc. (APVO) rose 73.4% to $0.581 on volume of 315,289,581 shares PROSHARES TRUST (SQQQ) rose 8.7% to $8.11 on volume of 173,682,364 sha...
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...
Rick Barry appointed Executive Chairman of the Board Remi Barbier resigns as President and CEO and from the Board of Directors Cassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the Boa...